M-VAC or MVC for the treatment of advanced transitional cell carcinoma: Metastatic, induction, and adjuvant

M. S. Soloway, S. Ishikawa, T. Taylor, G. Ezell

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The cisplatin-based combination chemotherapy regimens of M-VAC (methotrexate, vinblastine, doxorubicin, cisplatin) or MVC (methotrexate, vincristine, cisplatin) were given to 25 patients with metastatic urothelial carcinoma, 13 with locally advanced bladder cancer, and 10 as adjuvant therapy after radical surgery. Toxicity was significant with two deaths. Forty-eight percent of the patients with metastatic disease had a complete (20%) or partial (28%) response. Survival was only improved if a CR was achieved. Nine of 13 patients given M-VAC/MVC as neoadjuvant therapy underwent cystectomy and six are free of disease (mean 31 months). Three of the four patients who did not have radical surgery are also free of disease. These regimens appear to be superior to cisplatin alone. In the overall response evaluation, however, toxicity is greater.

Original languageEnglish
Pages (from-to)40-45
Number of pages6
JournalJournal of Surgical Oncology
Volume41
Issue numberSUPPL. 1
StatePublished - Jan 1 1989
Externally publishedYes

Fingerprint

Vinblastine
Transitional Cell Carcinoma
Vincristine
Methotrexate
Doxorubicin
Cisplatin
Therapeutics
Neoadjuvant Therapy
Cystectomy
Combination Drug Therapy
Urinary Bladder Neoplasms
Carcinoma
Survival

ASJC Scopus subject areas

  • Oncology
  • Surgery
  • Medicine(all)

Cite this

M-VAC or MVC for the treatment of advanced transitional cell carcinoma : Metastatic, induction, and adjuvant. / Soloway, M. S.; Ishikawa, S.; Taylor, T.; Ezell, G.

In: Journal of Surgical Oncology, Vol. 41, No. SUPPL. 1, 01.01.1989, p. 40-45.

Research output: Contribution to journalArticle

Soloway, MS, Ishikawa, S, Taylor, T & Ezell, G 1989, 'M-VAC or MVC for the treatment of advanced transitional cell carcinoma: Metastatic, induction, and adjuvant', Journal of Surgical Oncology, vol. 41, no. SUPPL. 1, pp. 40-45.
Soloway, M. S. ; Ishikawa, S. ; Taylor, T. ; Ezell, G. / M-VAC or MVC for the treatment of advanced transitional cell carcinoma : Metastatic, induction, and adjuvant. In: Journal of Surgical Oncology. 1989 ; Vol. 41, No. SUPPL. 1. pp. 40-45.
@article{e993e72848c54c55b67ac81b9fedeeb4,
title = "M-VAC or MVC for the treatment of advanced transitional cell carcinoma: Metastatic, induction, and adjuvant",
abstract = "The cisplatin-based combination chemotherapy regimens of M-VAC (methotrexate, vinblastine, doxorubicin, cisplatin) or MVC (methotrexate, vincristine, cisplatin) were given to 25 patients with metastatic urothelial carcinoma, 13 with locally advanced bladder cancer, and 10 as adjuvant therapy after radical surgery. Toxicity was significant with two deaths. Forty-eight percent of the patients with metastatic disease had a complete (20{\%}) or partial (28{\%}) response. Survival was only improved if a CR was achieved. Nine of 13 patients given M-VAC/MVC as neoadjuvant therapy underwent cystectomy and six are free of disease (mean 31 months). Three of the four patients who did not have radical surgery are also free of disease. These regimens appear to be superior to cisplatin alone. In the overall response evaluation, however, toxicity is greater.",
author = "Soloway, {M. S.} and S. Ishikawa and T. Taylor and G. Ezell",
year = "1989",
month = "1",
day = "1",
language = "English",
volume = "41",
pages = "40--45",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "SUPPL. 1",

}

TY - JOUR

T1 - M-VAC or MVC for the treatment of advanced transitional cell carcinoma

T2 - Metastatic, induction, and adjuvant

AU - Soloway, M. S.

AU - Ishikawa, S.

AU - Taylor, T.

AU - Ezell, G.

PY - 1989/1/1

Y1 - 1989/1/1

N2 - The cisplatin-based combination chemotherapy regimens of M-VAC (methotrexate, vinblastine, doxorubicin, cisplatin) or MVC (methotrexate, vincristine, cisplatin) were given to 25 patients with metastatic urothelial carcinoma, 13 with locally advanced bladder cancer, and 10 as adjuvant therapy after radical surgery. Toxicity was significant with two deaths. Forty-eight percent of the patients with metastatic disease had a complete (20%) or partial (28%) response. Survival was only improved if a CR was achieved. Nine of 13 patients given M-VAC/MVC as neoadjuvant therapy underwent cystectomy and six are free of disease (mean 31 months). Three of the four patients who did not have radical surgery are also free of disease. These regimens appear to be superior to cisplatin alone. In the overall response evaluation, however, toxicity is greater.

AB - The cisplatin-based combination chemotherapy regimens of M-VAC (methotrexate, vinblastine, doxorubicin, cisplatin) or MVC (methotrexate, vincristine, cisplatin) were given to 25 patients with metastatic urothelial carcinoma, 13 with locally advanced bladder cancer, and 10 as adjuvant therapy after radical surgery. Toxicity was significant with two deaths. Forty-eight percent of the patients with metastatic disease had a complete (20%) or partial (28%) response. Survival was only improved if a CR was achieved. Nine of 13 patients given M-VAC/MVC as neoadjuvant therapy underwent cystectomy and six are free of disease (mean 31 months). Three of the four patients who did not have radical surgery are also free of disease. These regimens appear to be superior to cisplatin alone. In the overall response evaluation, however, toxicity is greater.

UR - http://www.scopus.com/inward/record.url?scp=0024377620&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024377620&partnerID=8YFLogxK

M3 - Article

C2 - 2765094

AN - SCOPUS:0024377620

VL - 41

SP - 40

EP - 45

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - SUPPL. 1

ER -